In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spike
Note A, Nag, Moschovou, Kandeil, Singh (B), Boseila (and specifically the receptor binding domain
Note B, Kant, Srivastava, Eleraky), M
pro Note C, Moschovou, Kandeil, Srivastava, Naderi Beni, Rajagopal, Rampogu, Sekiou, Singh, Winih Kinasih, Thapa, Bahun, Eleraky, Boseila, RNA-dependent RNA polymerase
Note D, Singh (C), Eleraky, ACE2
Note E, Singh (B), Thapa, Alkafaas, nucleocapsid
Note F, Hidayah, Suravajhala, and nsp10
Note G, Suravajhala proteins.
In Vitro studies demonstrate inhibition of the spike
Note A, Mohd Abd Razak (and specifically the receptor binding domain
Note B, Goc (B)), M
pro Note C, Bahun, Guijarro-Real, Mohd Abd Razak, Wu, ACE2
Note E, Goc (B), and TMPRSS2
Note H, Goc (B) proteins.
In Vitro studies demonstrate efficacy in Calu-3
Note I, Bormann, A549
Note J, Mohd Abd Razak, 293T
Note K, Zhang, HEK293-hACE2
Note L, Nittayananta, Wu, 293T/hACE2/TMPRSS2
Note M, Septisetyani, and Vero E6
Note N, Bormann, Eleraky, Kandeil, Leka, Mohd Abd Razak, Nittayananta, Singh, Teshima, Marín-Palma cells.
Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants
Kant, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells
Marín-Palma, and alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress
Zhang.